Postoperative Ileus

2
Pipeline Programs
3
Companies
3
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
1
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

3 companies ranked by most advanced pipeline stage

T-Therapeutics
T-TherapeuticsUK - Cambridge
1 program
1
DAMPhase 31 trial
Active Trials
NCT01863407UnknownEst. Nov 2014
Bausch Health
Bausch HealthQUEBEC, Quebec, Canada
1 program
1
IV MethylnaltrexonePhase 21 trial
Active Trials
NCT01367548CompletedEst. Dec 2004
Verona Pharma
Verona PharmaUK - London
1 program
Standard coffeeN/A1 trial
Active Trials
NCT04205058Unknown199Est. Dec 2021

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
T-TherapeuticsDAM
Bausch HealthIV Methylnaltrexone
Verona PharmaStandard coffee

Clinical Trials (3)

Total enrollment: 199 patients across 3 trials

NCT01863407T-TherapeuticsDAM

Study of Dexamethasone-Allantoin-Metronidazole (DAM) Solution in the Treatment of Post-Operative Ileus (POI)

Start: Apr 2013Est. completion: Nov 2014
Phase 3Unknown
NCT01367548Bausch HealthIV Methylnaltrexone

Intravenous (IV) Methylnaltrexone (MNTX) in the Prevention of Post-Operative Ileus

Start: Jul 2003Est. completion: Dec 2004
Phase 2Completed
NCT04205058Verona PharmaStandard coffee

Coffee After Pancreatic Surgery

Start: Sep 2019Est. completion: Dec 2021199 patients
N/AUnknown

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 late-stage (Phase 3) programs — potential near-term approvals
3 companies competing in this space